Preview

Атеротромбоз

Расширенный поиск

ПРИМЕНЕНИЕ ПИТАВАСТАТИНА У ЛИЦ ПОЖИЛОГО И СТАРЧЕСКОГО ВОЗРАСТА: ОПТИМАЛЬНОЕ СООТНОШЕНИЕ ПОЛЬЗЫ И РИСКА

https://doi.org/10.21518/2307-1109-2016-2-106-116

Полный текст:

Аннотация

В статье рассматриваются фармакологические и клинические аспекты применения питавастатина у лиц пожилого возраста. Приводятся данные о сравнительной эффективности и безопасности приема питавастатина у лиц 65 лет и старше. Обсуждаются результаты клинических исследований, которые составляют доказательные основы использования питавастатина с целью первичной и вторичной профилактики развития осложнений сердечно-сосудистых заболеваний при наличии показаний к применению умеренно интенсивных режимов терапии статинами.

Об авторах

С. Р. Гиляревский
РМАПО; НИИ скорой помощи им. Н.В. Склифосовского
Россия
д.м.н., профессор


И. М. Кузьмина
НИИ скорой помощи им. Н.В. Склифосовского
Россия
к.м.н.


М. В. Голшмид
РМАПО
Россия
к.м.н.


Г. Ю. Захарова
РМАПО
Россия
к.м.н.


И. И. Синицина
РМАПО
Россия
д.м.н., профессор


Список литературы

1. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atheroscle— rotic cardiovascular risks in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129(25 Suppl 2): 1-45.

2. Pavlovic J, Greenland P, Deckers JW et al. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study. JAMA Cardiol, 2016, 1: 708-713.

3. Yusuf S, Bosch J, Dagenais G et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med, 2016 May 26, 374: 2021-2031.

4. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008, 359: 2195-2207.

5. Ford I, Murray H, McCowan C, Packard CJ. Long Term Safety and Efficacy of Lowering LDL Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation, 2016, 133: 1073- 1080.

6. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015, 372: 2387-2397.

7. Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA, 2014, 312: 1136-1144.

8. Clegg A, Young J, Lliffe S et al. Frailty in elderly people. Lancet, 2013, 381(9868): 752-762.

9. Chamberlin KW, Baker WL. Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. Clin Interv Aging, 2015, 10: 733-740.

10. Livalo® (pitavastatin) [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc. 2013.

11. Baker WL, Datta R. Pitavastatin: a New 3-Hydroxy-3- Methylglutaryl Coenzyme A Reductase Inhibitor for the Treatment of Hyperlipidemia. Adv Ther, 2011, 28: 13-27.

12. Aoki T, Nishimura H, Nagakawa S et al. Pharmacologic profile of a novel synthetic inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. Arzneimittelforschung, 1997, 47: 904-909. 13. Morikawa S, Umetani M, Nakagawa S et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMGCoA reductase inhibitors in cultured human cells. J Atheroscler Thromb, 2000, 7: 138-144.

13. Suzuki H, Aoki T, Tamaki T et al. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis, 1999, 146: 259-270.

14. Saito Y. Critical appraisal of the role of pitavastatinin treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag, 2009, 5: 921-936.

15. Alagona P. Pitavastatin: evidence for its place in treatment of hyperc-holesterolemia. Core Evid, 2010, 5: 91-105.

16. Shimada S, Fujino H, Hojima J et al. Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes. Drug Metab Pharmacokinet, 2003, 18: 245-251.

17. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther, 2004, 311: 139-146.

18. Hasanuma T, Nakamura M, Yaji T et al. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Therap Med, 2003, 19: 381-389.

19. Morgan RE, Campbell SE, Yu CY et al. Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol, 2012, 60: 42-48.

20. Hui CK, Cheung MY, Lau GK. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol, 2004, 59: 291-297.

21. Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther, 2011, 28: 811-823.

22. Sponseller CA, Morgan RE, Kryzhanovski VA et al. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther, 2014, 36: 1211-1222.

23. Stender S, Budinski D, Gosho M, Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolemia or combined (mixed) dyslipidemia. Eur J Prev Cardiol, 2013, 20: 40-53.

24. Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol, 2013, 20: 29- 39.

25. US Food and Drug Administration. Clinical Review Pitavastatin. Center for Drug Evaluation and Research; 2009. Available from: http://www. accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s0 00_MedR_P1.pdf. Accessed January 29, 2015.

26. Warita S, Kawasaki M, Tanaka R et al. Effect of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients. A prospective study of 2-years’ follow-up. Circ J, 2012, 76: 2755-2762.

27. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin, 2009, 25: 2755-2765.

28. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis, 2010, 210: 202-208.

29. Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab, 2011, 13: 1047-1055.

30. Rodriquez Arroyo LA, Diaz Rodriquez A, Pinto Sata X et al. Effectivity and satisfaction with the treatment of dys— lipidemia with pitavastatin. Multicentric, descriptive, post authorized and observational study (REINA study)]. Clin Investig Arterioscler, 2014, 26: 205-217.

31. Blasetto JW, Stein EA, Brown WV et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol, 2003, 91: 3-10.

32. Harley CR, Gandhi S, Blasetto J et al. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother, 2007, 5: 185-194.

33. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol, 2011, 73: 18-35.

34. Richardon K, Schoen M, French B et al. Statins and cognitive function: a systematic review. Ann Intern Med, 2013, 159: 688-697.

35. Rojas-Fernandez CH, Goldstein LB, Levey AI et al.; The National Lipid Association’s Safety Task Force. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol, 2014, 8(3 Suppl): 5-16.

36. Macedo AF, Taylor FC, Casas JP et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med, 2014, 22: 51.

37. Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association’s Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol, 2014, 8(3 Suppl): 47-57.


Для цитирования:


Гиляревский С.Р., Кузьмина И.М., Голшмид М.В., Захарова Г.Ю., Синицина И.И. ПРИМЕНЕНИЕ ПИТАВАСТАТИНА У ЛИЦ ПОЖИЛОГО И СТАРЧЕСКОГО ВОЗРАСТА: ОПТИМАЛЬНОЕ СООТНОШЕНИЕ ПОЛЬЗЫ И РИСКА. Атеротромбоз. 2016;(2):116-127. https://doi.org/10.21518/2307-1109-2016-2-106-116

For citation:


., ., ., ., . . Atherothrombosis. 2016;(2):116-127. (In Russ.) https://doi.org/10.21518/2307-1109-2016-2-106-116

Просмотров: 212


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)